M. Bowden
All authors
About
Publications While At HealthPartners
selected publications
Journal Article
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
.
Lancet Oncology.
2016
Contact
full name
M.
Bowden
Quick Info
Collaboration
Co-author network
Map of science